Making the discoveries that defeat cancer

  • Home »
  • Research »
  • Repository

  • Administrators Login

  • Repository Homepage
  • About the Repository
  • Browse the Repository
  • Search the Repository
  • Contribute an Article
  • Missing Publications
  • Repository Help

Novel therapeutic approaches in chondrosarcoma

Tools
- Tools
+ Tools

Polychronidou, G., Karavasilis, V., Pollack, S. M., Huang, P. H., Lee, A., Jones, R. L. (2017) Novel therapeutic approaches in chondrosarcoma. FUTURE ONCOLOGY, 13 (7). pp. 637-648. ISSN 1479-6694

Full text not available from this repository.

A copy of the full text may be available at: http://www.futuremedicine.com/doi/10.2217/fon-2016...

Abstract

Chondrosarcoma is a malignant tumor of bones, characterized by the production of cartilage matrix. Due to lack of effective treatment for advanced disease, the clinical management of chondrosarcomas is exceptionally challenging. Current research focuses on elucidating the molecular events underlying the pathogenesis of this rare bone malignancy, with the goal of developing new molecularly targeted therapies. Signaling pathways suggested to have a role in chondrosarcoma include Hedgehog, Src, PI3k-Akt-mTOR and angiogenesis. Mutations in IDH1/2, present in more than 50% of primary conventional chondrosarcomas, make the development of IDH inhibitors a promising treatment option. The present review discusses the preclinical and early clinical data on novel targeted therapeutic approaches in chondrosarcoma.

Item Type: Review Article
Authors (ICR Faculty only): Huang, Paul and Jones, Robin
All Authors: Polychronidou, G., Karavasilis, V., Pollack, S. M., Huang, P. H., Lee, A., Jones, R. L.
Additional Information: ISI Document Delivery No.: EL1YC Times Cited: 0 Cited Reference Count: 99 Polychronidou, Genovefa Karavasilis, Vasilios Pollack, Seth M. Huang, Paul H. Lee, Alex Jones, Robin L. 0 FUTURE MEDICINE LTD LONDON FUTURE ONCOL
Uncontrolled Keywords: chondrosarcoma HDACIs Hedgehog pathway IDH1/2 novel agents Src pathway treatment SOFT-TISSUE SARCOMA HISTONE DEACETYLASE INHIBITORS T-CELL LYMPHOMA VEGF EXPRESSION DEPENDENT ANGIOGENESIS DASATINIB SENSITIZES CARTILAGINOUS TUMORS ANTIBODY CIXUTUMUMAB MONOCLONAL-ANTIBODY SIGNALING PATHWAY
Research teams: Clinical Units > Drug Development Unit
ICR divisions > Molecular Pathology > Protein Networks
ICR divisions > Clinical Studies > Sarcoma Clinical Trials in children and young people
ICR divisions > Molecular Pathology > Sarcoma Clinical Trials in children and young people

ICR divisions > Clinical Studies > Sarcoma Clinical Trials (R Jones)
Depositing User: Barry Jenkins
Date Deposited: 10 Apr 2017 14:35
Last Modified: 20 Feb 2018 10:51
URI: http://publications.icr.ac.uk/id/eprint/15825

Actions (login required)

View Item View Item
The Royal Marsden - NHS foundation trust